Solid Biosciences conducts digital transformations to advance its gene therapy development for Duchenne muscular dystrophy. These transformations center on implementing robust internal systems, integrating complex data streams, and digitizing critical workflows across research, clinical development, and quality operations. Their approach emphasizes system accuracy and regulatory compliance inherent in biotechnology.
These transformations create new system dependencies and introduce specific operational challenges. Managing vast clinical trial data, ensuring laboratory data integrity, and maintaining electronic quality controls become critical for success. This page will analyze these specific initiatives, their inherent challenges, and the resulting sales opportunities for vendors.
Solid Biosciences Snapshot
Headquarters: Charlestown, Massachusetts, United States
Number of employees: 121
Public or private: Public
Business model: B2B
Website: http://www.solidbio.com
Solid Biosciences ICP and Buying Roles
Solid Biosciences sells to specialized pharmaceutical companies and research institutions focused on rare disease therapies.
They also partner with contract research organizations managing complex clinical trials.
Who drives buying decisions
- Head of Clinical Operations → Ensures efficient clinical trial execution and data integrity
- VP of Research & Development → Oversees laboratory data management and scientific discovery platforms
- Head of Quality Assurance → Validates electronic quality control systems and regulatory compliance
- Chief Information Officer → Manages core enterprise systems and IT infrastructure development
Key Digital Transformation Initiatives at Solid Biosciences (At a Glance)
- Digitizing clinical data collection and trial management systems.
- Integrating laboratory information management across research workflows.
- Implementing electronic quality management for regulatory compliance processes.
- Upgrading enterprise resource planning for financial and supply chain operations.
- Developing bioinformatics data pipelines for genomic analysis.
Where Solid Biosciences’s Digital Transformation Creates Sales Opportunities
| Vendor Type | Where to Sell (DT Initiative + Challenge) | Buyer / Owner | Solution Approach |
|---|---|---|---|
| Clinical Data Management Platforms | Digitizing clinical data collection: patient data entry contains inconsistencies before database lock. | Head of Clinical Operations, VP of Regulatory Affairs | Standardize data capture forms and enforce validation rules at point of entry. |
| Clinical trial management systems: site monitoring data does not propagate to central trial records. | Head of Clinical Operations, Clinical Trial Manager | Route monitoring reports and sync data points between systems without manual reconciliation. | |
| Clinical data analysis: disparate data sources complicate regulatory submission reporting. | VP of Biometrics, VP of Regulatory Affairs | Aggregate clinical data from varied systems into a unified reporting framework. | |
| Laboratory Information Systems | Integrating laboratory information management: sample tracking records do not update across instruments. | VP of Research & Development, Lab Director | Standardize sample identifiers and enforce data synchronization between lab equipment and LIMS. |
| Lab experiment workflows: raw instrument data formats create inconsistencies in downstream analysis. | VP of Research & Development, Head of Bioinformatics | Validate instrument output data structures before ingestion into analysis platforms. | |
| ELN data capture: research notes are not linked to specific assay results for audit trails. | Lab Director, Head of Quality Assurance | Enforce linking of experimental records to raw data and results for full traceability. | |
| Quality Management System Tools | Implementing electronic quality management: manual reviews block deviation and CAPA workflows. | Head of Quality Assurance, Director of Compliance | Route deviations and CAPAs for automated review and approval based on predefined criteria. |
| eQMS document control: outdated versions of SOPs are used in manufacturing due to slow distribution. | Director of Manufacturing, Head of Quality Assurance | Enforce document version control and automate distribution of approved quality documents. | |
| Audit management: audit findings require manual assignment and tracking across departments. | Head of Quality Assurance, Internal Audit Manager | Standardize audit finding categorization and route actions to specific owners for resolution. | |
| ERP Integration Platforms | Upgrading enterprise resource planning: financial transaction data does not sync with project costing. | Head of Finance, Chief Information Officer | Validate data transfer between sub-ledgers and the general ledger for accurate project expense allocation. |
| Clinical supply chain tracking: material orders do not reflect real-time inventory levels in ERP. | Director of Supply Chain, Head of Clinical Operations | Enforce real-time inventory updates from logistics partners into the ERP system. | |
| Procurement for R&D materials: vendor invoice data does not match purchase order details in ERP. | Head of Procurement, Accounts Payable Manager | Validate invoice line items against purchase orders to prevent payment discrepancies. | |
| Bioinformatics Data Platforms | Developing bioinformatics data pipelines: genomic sequencing data contains errors after processing. | Head of Bioinformatics, VP of Research & Development | Detect data quality issues within the pipeline before variant calling. |
| Research data sharing: large scientific datasets are not accessible to collaborators across systems. | VP of Research & Development, IT Infrastructure Manager | Standardize data formats for sharing across internal and external research platforms. |
Identify when companies like Solid Biosciences are in-market for your solutions.
Spot buying signals, find the right prospects, enrich your data, and reach out with relevant messaging at the right time.
What makes this Solid Biosciences’s digital transformation unique
Solid Biosciences heavily prioritizes data integrity and regulatory compliance across its digital transformation initiatives. Their approach is unique because it integrates scientific discovery platforms with rigorous quality management systems. This creates a dependency on robust data validation and auditable workflows from early research through clinical development. Their transformation is more complex due to the strict regulatory environment governing gene therapies.
Solid Biosciences’s Digital Transformation: Operational Breakdown
DT Initiative 1: Digitizing clinical data collection and trial management systems
What the company is doing
Solid Biosciences implements new Electronic Data Capture (EDC) systems for patient data collection in clinical trials. They are also deploying Clinical Trial Management Systems (CTMS) to oversee trial progress and site activities. This transforms how clinical trial data is acquired and managed.
Who owns this
- Head of Clinical Operations
- VP of Regulatory Affairs
- Clinical Data Manager
Where It Fails
- Patient data entry contains inconsistencies before database lock in EDC systems.
- Site monitoring data does not propagate to central trial records within CTMS.
- Clinical data from disparate sources complicate regulatory submission reporting.
- Trial milestones in CTMS are not updated automatically from site activities.
- Investigator training records are not consistently linked to system access permissions.
Talk track
Noticed Solid Biosciences is digitizing clinical data collection and trial management. Been looking at how some biotech teams are enforcing data validation at the point of entry instead of cleaning data later, can share what’s working if useful.
DT Initiative 2: Integrating laboratory information management across research workflows
What the company is doing
Solid Biosciences connects Lab Information Management Systems (LIMS) with Electronic Lab Notebooks (ELN) and instrument software. This integrates sample tracking, experiment execution, and raw data capture for research and development. The company standardizes data flow between lab equipment and central data repositories.
Who owns this
- VP of Research & Development
- Lab Director
- Head of Bioinformatics
Where It Fails
- Sample tracking records do not update across instruments after an experiment run.
- Raw instrument data formats create inconsistencies in downstream bioinformatics analysis platforms.
- Research notes in ELN are not linked to specific assay results for audit trails.
- Data from analytical instruments requires manual upload into the LIMS system.
- Reagent lot numbers are not automatically validated against experimental protocols.
Talk track
Saw Solid Biosciences is integrating laboratory information management across research. Been looking at how some R&D teams are standardizing sample identifiers and enforcing data synchronization between lab equipment and LIMS, happy to share what we’re seeing.
DT Initiative 3: Implementing electronic quality management for regulatory compliance processes
What the company is doing
Solid Biosciences adopts electronic Quality Management Systems (eQMS) to manage documentation, deviations, and corrective actions. This digitizes critical quality processes required for regulatory compliance in gene therapy development. They enforce digital workflows for change control and audit management.
Who owns this
- Head of Quality Assurance
- Director of Compliance
- Internal Audit Manager
Where It Fails
- Manual reviews block deviation and CAPA workflows within the eQMS.
- Outdated versions of SOPs are used in manufacturing due to slow document distribution.
- Audit findings require manual assignment and tracking across departments for resolution.
- Training records are not automatically updated after new quality procedure deployment.
- Change control requests are routed incorrectly, causing delays in system updates.
Talk track
Looks like Solid Biosciences is implementing electronic quality management for compliance. Been seeing teams route deviations and CAPAs for automated review and approval based on predefined criteria, can share what’s working if useful.
DT Initiative 4: Upgrading enterprise resource planning for financial and supply chain operations
What the company is doing
Solid Biosciences upgrades its Enterprise Resource Planning (ERP) system to manage financial processes, clinical supply chain, and procurement. This integrates core business operations and streamlines transaction handling. The company standardizes financial reporting and inventory tracking for clinical materials.
Who owns this
- Head of Finance
- Chief Information Officer
- Director of Supply Chain
Where It Fails
- Financial transaction data does not sync accurately with project costing in the ERP.
- Clinical material orders do not reflect real-time inventory levels in the ERP system.
- Vendor invoice data does not match purchase order details, requiring manual reconciliation.
- Procurement requests are not automatically routed to approved vendors for R&D supplies.
- Budget reporting by department contains discrepancies due to inconsistent GL coding.
Talk track
Noticed Solid Biosciences is upgrading enterprise resource planning for operations. Been looking at how some finance teams are validating data transfer between sub-ledgers and the general ledger for accurate project expense allocation, happy to share what we’re seeing.
DT Initiative 5: Developing bioinformatics data pipelines for genomic analysis
What the company is doing
Solid Biosciences develops specialized bioinformatics pipelines to process and analyze large genomic and proteomic datasets. This involves integrating high-performance computing resources with analytical tools for gene therapy research. The company standardizes data ingestion and variant calling workflows.
Who owns this
- Head of Bioinformatics
- VP of Research & Development
- IT Infrastructure Manager
Where It Fails
- Genomic sequencing data contains errors after initial processing within the pipeline.
- Large scientific datasets are not accessible to collaborators across different research platforms.
- Data integrity issues arise during transfer from sequencing facilities to internal storage.
- Analysis results are not consistently linked back to raw data for verification.
- Computational models produce inconsistent results due to varying data inputs.
Talk track
Saw Solid Biosciences is developing bioinformatics data pipelines for analysis. Been looking at how some research teams are detecting data quality issues within the pipeline before variant calling, can share what’s working if useful.
Who Should Target Solid Biosciences Right Now
This account is relevant for:
- Clinical Data Management Solution Providers
- Laboratory Information Management System (LIMS) Vendors
- Electronic Quality Management System (eQMS) Software Companies
- ERP Integration and Data Synchronization Platforms
- Bioinformatics Data Pipeline Monitoring Tools
Not a fit for:
- Basic project management tools without clinical trial features
- Generic HR payroll systems without complex ERP integration
- Standalone marketing automation platforms
- Consumer-facing e-commerce solutions
When Solid Biosciences Is Worth Prioritizing
Prioritize if:
- You sell tools for enforcing data validation rules in clinical data capture systems.
- You sell solutions that standardize sample identifiers and synchronize lab instrument data.
- You sell platforms that automate routing and approval for quality deviations and CAPAs.
- You sell solutions for real-time data transfer and reconciliation between ERP modules.
- You sell tools for detecting data quality issues within bioinformatics processing pipelines.
Deprioritize if:
- Your solution does not address any of the breakdowns above.
- Your product is limited to basic functionality without advanced regulatory compliance features.
- Your offering is not built for complex scientific data or enterprise system integrations.
Who Can Sell to Solid Biosciences Right Now
Clinical Data Governance Platforms
Veeva Systems - This company provides cloud-based software for the global life sciences industry, focusing on clinical, regulatory, and quality solutions.
Why they are relevant: Patient data entry contains inconsistencies before database lock in EDC systems, creating delays. Veeva can enforce structured data capture and validation rules within clinical workflows, preventing errors before data lock.
Medidata Solutions - This company offers a unified platform for clinical research, including EDC, CTMS, and data analytics tools.
Why they are relevant: Site monitoring data does not propagate to central trial records, impacting oversight. Medidata can ensure seamless data flow from source to centralized repositories, improving trial visibility and integrity.
Laboratory Informatics Solutions
Thermo Fisher Scientific (SampleManager LIMS) - This company provides comprehensive laboratory information management systems for various industries, including biotech.
Why they are relevant: Sample tracking records do not update across instruments after an experiment run. SampleManager LIMS can standardize sample identifiers and integrate directly with lab equipment, ensuring real-time data updates.
Labguru - This company offers an electronic lab notebook (ELN) and lab management system that helps centralize research data.
Why they are relevant: Research notes in ELN are not linked to specific assay results for audit trails. Labguru can enforce strict linking between experimental procedures, raw data, and outcomes, providing a complete audit trail.
Electronic Quality Management Systems (eQMS)
MasterControl - This company provides cloud-based QMS software designed for life sciences companies to manage quality processes and regulatory compliance.
Why they are relevant: Manual reviews block deviation and CAPA workflows within the eQMS, causing delays. MasterControl can automate the routing and approval of quality events, enforcing compliance and speeding resolution.
Sparta Systems (TrackWise) - This company offers enterprise quality management solutions for regulated industries, including CAPA, audit, and document control.
Why they are relevant: Outdated versions of SOPs are used in manufacturing due to slow document distribution. TrackWise can enforce version control and automate distribution of approved quality documents, preventing compliance issues.
ERP Integration & Data Validation
Boomi - This company offers an integration platform as a service (iPaaS) that connects applications, data, and devices across hybrid environments.
Why they are relevant: Financial transaction data does not sync accurately with project costing in the ERP. Boomi can validate and route financial data between sub-ledgers and the general ledger, ensuring accurate project expense allocation.
Celigo - This company provides an integration platform that automates business processes across applications like ERP, CRM, and e-commerce.
Why they are relevant: Vendor invoice data does not match purchase order details, requiring manual reconciliation. Celigo can automate validation of invoice line items against purchase orders before ERP posting, reducing manual effort and errors.
Bioinformatics Data Integrity Tools
DNAnexus - This company provides a cloud-based platform for genomic and multi-omic data analysis and management.
Why they are relevant: Genomic sequencing data contains errors after initial processing within the pipeline. DNAnexus can implement quality checks and validation steps within the bioinformatics pipeline, detecting data issues before analysis.
Seven Bridges Genomics - This company offers a biomedical data analysis platform for researchers and clinicians to accelerate discovery.
Why they are relevant: Large scientific datasets are not accessible to collaborators across different research platforms. Seven Bridges can standardize data formats and access protocols, enabling secure data sharing and collaboration.
Final Take
Solid Biosciences scales internal systems for clinical trials, lab management, and quality control. Breakdowns are visible in data inconsistencies, manual reconciliation in workflows, and system integration gaps across research and operations. This account is a strong fit for vendors that offer solutions preventing data failures and enforcing compliance within highly regulated biotech environments.
Identify buying signals from digital transformation at your target companies and find those already in-market.
Find the right contacts and use tailored messages to reach out with context.